转移性-话题@MedSci

#转移性#

975篇内容 | 3361人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1386576, encodeId=b68813865e618, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌, objectType=article, longId=184900, objectId=b47618490022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b47618490022, replyNumber=0, likeNumber=68, createdTime=2019-12-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b47618490022, moduleTitle=恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b47618490022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386575, encodeId=c09313865e58b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：CD4/6抑制剂用于激素受体阳性、HER2阴性转移性乳腺癌, objectType=article, longId=184893, objectId=50041848939a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50041848939a, replyNumber=0, likeNumber=68, createdTime=2019-12-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50041848939a, moduleTitle=Lancet Oncol：CD4/6抑制剂用于激素受体阳性、HER2阴性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50041848939a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386574, encodeId=128713865e4a1, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=2019 多学科共识文件：转移性激素敏感和转移性去势抵抗性前列腺癌患者的监测, objectType=article, longId=184869, objectId=7cbd18486903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cbd18486903, replyNumber=0, likeNumber=35, createdTime=2019-12-18, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cbd18486903, moduleTitle=2019 多学科共识文件：转移性激素敏感和转移性去势抵抗性前列腺癌患者的监测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cbd18486903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386573, encodeId=344c13865e3b6, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, objectType=article, longId=184671, objectId=d1461846e154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1461846e154, replyNumber=0, likeNumber=81, createdTime=2019-12-14, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1461846e154, moduleTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1461846e154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386572, encodeId=ff6413865e2f4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , objectType=article, longId=184672, objectId=90f01846e265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90f01846e265, replyNumber=0, likeNumber=79, createdTime=2019-12-14, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90f01846e265, moduleTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90f01846e265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386571, encodeId=d8bd13865e1a4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌, objectType=article, longId=184670, objectId=4c281846e069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c281846e069, replyNumber=0, likeNumber=59, createdTime=2019-12-14, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c281846e069, moduleTitle=NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c281846e069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386570, encodeId=bf0913865e081, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet oncol：Tivozanib治疗转移性肾细胞癌！, objectType=article, longId=184622, objectId=33e318462202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e318462202, replyNumber=0, likeNumber=52, createdTime=2019-12-13, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e318462202, moduleTitle=Lancet oncol：Tivozanib治疗转移性肾细胞癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e318462202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386569, encodeId=c3071386569b5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=转移性前列腺癌该如何化疗, objectType=article, longId=184319, objectId=581e1843194a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=581e1843194a, replyNumber=0, likeNumber=61, createdTime=2019-12-08, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=581e1843194a, moduleTitle=转移性前列腺癌该如何化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=581e1843194a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386568, encodeId=04bd13865689f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, objectType=article, longId=184290, objectId=431b184290f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431b184290f9, replyNumber=0, likeNumber=69, createdTime=2019-12-08, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431b184290f9, moduleTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=431b184290f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386567, encodeId=7353138656edd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JAMA：恶性转移性实体瘤和椎管压迫患者放疗方案, objectType=article, longId=184241, objectId=613018424191, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=613018424191, replyNumber=0, likeNumber=67, createdTime=2019-12-07, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=613018424191, moduleTitle=JAMA：恶性转移性实体瘤和椎管压迫患者放疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=613018424191)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386566, encodeId=be6c1386566d3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=转移性前列腺癌化疗中国专家共识（2019版）, objectType=article, longId=184157, objectId=54c918415ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54c918415ed0, replyNumber=0, likeNumber=34, createdTime=2019-12-05, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54c918415ed0, moduleTitle=转移性前列腺癌化疗中国专家共识（2019版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54c918415ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386565, encodeId=28891386565f0, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌, objectType=article, longId=184022, objectId=bfe4184022fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfe4184022fb, replyNumber=0, likeNumber=84, createdTime=2019-12-04, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfe4184022fb, moduleTitle=英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfe4184022fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386564, encodeId=5f7d1386564f5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=喜大普奔！帕博利珠单抗联合化疗一线治疗转移性鳞状非小细胞肺癌在华获批, objectType=article, longId=184012, objectId=576f184012f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=576f184012f8, replyNumber=0, likeNumber=72, createdTime=2019-12-04, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=576f184012f8, moduleTitle=喜大普奔！帕博利珠单抗联合化疗一线治疗转移性鳞状非小细胞肺癌在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=576f184012f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386563, encodeId=d2cd13865631e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间, objectType=article, longId=183719, objectId=f1bc183e1902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bc183e1902, replyNumber=0, likeNumber=93, createdTime=2019-11-30, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bc183e1902, moduleTitle=2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bc183e1902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386562, encodeId=e741138656265, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164, objectType=article, longId=183247, objectId=74bf18324ece, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74bf18324ece, replyNumber=0, likeNumber=35, createdTime=2019-11-21, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74bf18324ece, moduleTitle=JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74bf18324ece)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386561, encodeId=54fb1386561c1, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Prostate Cancer P D：接受重症监护治疗的转移性前列腺癌患者接受姑息治疗的当前趋势和社会障碍研究, objectType=article, longId=183223, objectId=46cf183223b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46cf183223b5, replyNumber=0, likeNumber=132, createdTime=2019-11-21, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46cf183223b5, moduleTitle=Prostate Cancer P D：接受重症监护治疗的转移性前列腺癌患者接受姑息治疗的当前趋势和社会障碍研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46cf183223b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386560, encodeId=0a13138656074, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：醋酸阿比特龙+恩杂鲁胺治疗转移性去势抵抗性前列腺癌的更佳顺序, objectType=article, longId=183078, objectId=978d1830e88d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=978d1830e88d, replyNumber=0, likeNumber=63, createdTime=2019-11-17, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=978d1830e88d, moduleTitle=Lancet Oncol：醋酸阿比特龙+恩杂鲁胺治疗转移性去势抵抗性前列腺癌的更佳顺序, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=978d1830e88d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386559, encodeId=1c151386559fc, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请, objectType=article, longId=182599, objectId=86501825990a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86501825990a, replyNumber=0, likeNumber=57, createdTime=2019-11-09, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86501825990a, moduleTitle=基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86501825990a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386558, encodeId=551113865587e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=BioLineRx宣布其CXCL4拮抗剂BL-8040与Keytruda联合治疗转移性胰腺癌的2b临床活性, objectType=article, longId=182514, objectId=bed218251491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed218251491, replyNumber=0, likeNumber=78, createdTime=2019-11-08, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed218251491, moduleTitle=BioLineRx宣布其CXCL4拮抗剂BL-8040与Keytruda联合治疗转移性胰腺癌的2b临床活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed218251491)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386557, encodeId=97f9138655e28, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet：Pembrolizumab治疗复发或转移性头颈部鳞状细胞癌, objectType=article, longId=182385, objectId=dc141823856a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc141823856a, replyNumber=0, likeNumber=63, createdTime=2019-11-06, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc141823856a, moduleTitle=Lancet：Pembrolizumab治疗复发或转移性头颈部鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc141823856a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌

2019-12-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：CD4/6抑制剂用于激素受体阳性、HER2阴性转移性乳腺癌

2019-12-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

2019 多学科共识文件：转移性激素敏感和转移性去势抵抗性前列腺癌患者的监测

2019-12-18

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗

2019-12-14

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 

2019-12-14

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌

2019-12-14

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet oncol：Tivozanib治疗转移性肾细胞癌！

2019-12-13

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

转移性前列腺癌该如何化疗

2019-12-08

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌

2019-12-08

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JAMA：恶性转移性实体瘤和椎管压迫患者放疗方案

2019-12-07

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

转移性前列腺癌化疗中国专家共识（2019版）

2019-12-05

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌

2019-12-04

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

喜大普奔！帕博利珠单抗联合化疗一线治疗转移性鳞状非小细胞肺癌在华获批

2019-12-04

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间

2019-11-30

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164

2019-11-21

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Prostate Cancer P D：接受重症监护治疗的转移性前列腺癌患者接受姑息治疗的当前趋势和社会障碍研究

2019-11-21

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：醋酸阿比特龙+恩杂鲁胺治疗转移性去势抵抗性前列腺癌的更佳顺序

2019-11-17

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请

2019-11-09

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

BioLineRx宣布其CXCL4拮抗剂BL-8040与Keytruda联合治疗转移性胰腺癌的2b临床活性

2019-11-08

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet：Pembrolizumab治疗复发或转移性头颈部鳞状细胞癌

2019-11-06

科室
- - 订阅+
  - 更多科室
工具
服务